Search results

Skip to results

Area of interest

Type

Status

Last updated

Showing 2206 to 2220 of 7960 results

  1. Tislelizumab with platinum-based chemotherapy and etoposide for untreated extensive-stage small-cell lung cancer [ID6158]

    Awaiting development [GID-TA11094] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development [GID-TA11517] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent [ID6207]

    In development [GID-TA11235] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development [GID-TA11281] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]

    In development [GID-TA11500] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development [GID-TA11470] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]

    In development [GID-TA11400] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Pembrolizumab with chemotherapy for treating platinum-resistant recurrent ovarian cancer after 1 or 2 treatments [ID6363]

    In development [GID-TA11422] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development [GID-TA10664] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. DOASENSE DOAC dipstick product for the detection of direct oral anti-coagulants

      Status ...

    Diagnostics guidance
    Topic selection

  11. CytoSorb for reducing risk of bleeding during cardiac surgery

      Status ...

    Medical technologies guidance
    Topic selection

  12. Moor LDLS-BI for assessing burn depth and healing potential in children and adults

      Status ...

    Medical technologies guidance
    Topic selection

  13. The Stak for knee stretching following knee replacement or injury or to treat osteoarthritis

      Status ...

    Medical technologies guidance
    Topic selection

  14. URO17 for testing suspected bladder cancer

      Status ...

    Diagnostics guidance
    Topic selection

  15. RenalSense Clarity RMS for acute kidney injury MT601 (MIB256)

      Status ...

    Medical technologies guidance
    Topic selection